Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Osaka and Tokyo, Japan, July 1, 2011 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”;...
Tokyo, Japan, July 1, 2011 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) today announced that Betanis® tablet (generic name:mirabegron) was...
Read more about Approval for Betanis® tablet, a Treatment for OAB, in Japan
TOKYO, June 21, 2011 ─ Astellas Pharma Inc. (“Astellas”; Tokyo:4503) and Abbott Japan Co., Ltd. (“Abbott”) today announced that Astellas will transfer the rights to distribute the...
Read more about Transfer of Distribution Rights for SSRI "Luvox® Tablets"
Japan, June 20, 2011 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka,“Astellas”) announces that today it appointed Yasumasa Masuda as Corporate Executive,...
Follow us
